- Home
- MRSN vs DYAI Comparison
MRSN vs DYAI Comparison
Compare MRSN & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- DYAI
- Stock Information
- Founded
- MRSN 2001
- DYAI 1979
- Country
- MRSN United States
- DYAI United States
- Employees
- MRSN N/A
- DYAI N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MRSN Health Care
- DYAI Health Care
- Exchange
- MRSN Nasdaq
- DYAI Nasdaq
- Market Cap
- MRSN 40.7M
- DYAI 35.5M
- IPO Year
- MRSN 2017
- DYAI 2004
- Fundamental
- Price
- MRSN $0.32
- DYAI $1.07
- Analyst Decision
- MRSN Buy
- DYAI Strong Buy
- Analyst Count
- MRSN 3
- DYAI 1
- Target Price
- MRSN $4.00
- DYAI $6.00
- AVG Volume (30 Days)
- MRSN 2.3M
- DYAI 35.9K
- Earning Date
- MRSN 05-15-2025
- DYAI 05-14-2025
- Dividend Yield
- MRSN N/A
- DYAI N/A
- EPS Growth
- MRSN N/A
- DYAI N/A
- EPS
- MRSN N/A
- DYAI N/A
- Revenue
- MRSN $40,497,000.00
- DYAI $3,495,389.00
- Revenue This Year
- MRSN N/A
- DYAI $117.40
- Revenue Next Year
- MRSN N/A
- DYAI N/A
- P/E Ratio
- MRSN N/A
- DYAI N/A
- Revenue Growth
- MRSN 9.88
- DYAI 20.58
- 52 Week Low
- MRSN $0.26
- DYAI $0.93
- 52 Week High
- MRSN $3.50
- DYAI $2.67
- Technical
- Relative Strength Index (RSI)
- MRSN 41.87
- DYAI 28.15
- Support Level
- MRSN $0.35
- DYAI $1.05
- Resistance Level
- MRSN $0.44
- DYAI $1.21
- Average True Range (ATR)
- MRSN 0.04
- DYAI 0.07
- MACD
- MRSN -0.00
- DYAI -0.01
- Stochastic Oscillator
- MRSN 8.48
- DYAI 8.33
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.